BACK Rgenta Therapeutics recipient of the Servier’s 2020 LabCentral Golden Ticket Paris (France) and Cambridge (U.S.), May 5, 2020 – Servier has awarded the 2020 Servier Golden Ticket at LabCentral to Rgenta Therapeutics, a new biotechnology company focusing on developing RNA-targeting medicines for historically undruggable disease-relevant targets. The award will help Rgenta Therapeutics advance the company’s pursuit of high-value oral, small molecule RNA targets in a range of therapeutic areas, including oncology and neurology. The Golden Ticket award This coveted prize from Servier, part of its sponsorship of LabCentral, supports a startup research program that aligns with Servier’s ambitious efforts to deliver meaningful improvements in patient care today and into the future. The Golden Ticket award underwrites the cost of one lab bench for one scientist to reside in LabCentral’s open lab for one year, allowing a startup company to focus its early efforts on moving the science forward. A unique discovery engine at RgentaTherapeutics Rgenta is built on a robust discovery platform that delivers an innovative approach that gives it access to historically undruggable, highly disease-relevant targets. Utilizing large-scale genomics data and a proprietary bioinformatic analysis platform, Rgenta is able to identify regulatory sites in RNAs amenable for potent and selective modulation by small molecules. This unique discovery engine can rapidly screen for drug-like small molecules to target RNAs and thereby regulate protein production or alter protein function, opening up unprecedented opportunities for drug development. — About Servier Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a total revenue of 4.6 billion euros in 2019, Servier employs 22,000 people worldwide. Entirely independent, the Group invests on average 25% of its total revenue (excluding generics) every year in research and development and uses all its profits for its development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory, and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. More information: www.servier.com Press contacts: Sonia Marques : presse@servier.com – Tel. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13 Jean-Clément Vergeau : presse@servier.com – Tel. +33 (0)1 55 46 16 / +33 6 79 56 75 96 About LabCentral LabCentral is a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups. It offers fully permitted laboratory and office space for as many as 60 startups comprising approximately 200 scientists and entrepreneurs. LabCentral provides first-class facility and administrative support, skilled laboratory personnel, a domain-relevant expert speaker series ‒ as well as the other critical services and support that early-stage companies need to begin laboratory operations on day one. A private, nonprofit institution, LabCentral was funded in part by two $5 million grants from the Massachusetts Life Sciences Center, with support from its real-estate partner, MIT. Press contact: Lindsay Michelle Crockett: lcrockett@labcentral.org About Rgenta Therapeutics Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Our lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. Learn more at http://www.rgentatx.com. Press contact: Rgenta Therapeutics: media@rgentatx.com 05/05/2020 Other news © 2019 LES LABORATOIRES SERVIER This site is intended for United Kingdom residents Servier does not sell its products over the Internet Terms of Use Data Privacy Cookies notice Report a side effect Servier Clinical Trials M-NO-UK-00444 Date of Preparation January 2021